A phase I randomized, double-blind, placebo-controlled, multi-dose study of PBI 4050 in patients with diabetic nephropathies

Trial Profile

A phase I randomized, double-blind, placebo-controlled, multi-dose study of PBI 4050 in patients with diabetic nephropathies

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2015

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Diabetic nephropathies
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 15 Nov 2015 Results from this phase Ib study have been presented at the American Society of Nephrology (ASN) annual meeting.
    • 19 Mar 2015 Status changed from active, no longer recruiting to completed according to a ProMetic Life Sciences media release.
    • 17 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to a ProMetic Life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top